Status:
COMPLETED
Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Conditions:
Hepatitis C
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.
Eligibility Criteria
Inclusion
- Healthy males, and/or healthy females of non-childbearing potential, aged 18 to 55 years (inclusive)
- Body mass index (BMI) between 18 and 31 kg/m2 (inclusive) and weight \> 50 kg
Exclusion
- Women of child bearing potential
- Subjects positive for Hepatitis B, Hepatitis C, or HIV
- Subjects who have participated in a clinical study involving administration of an investigational drug within 2 months
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00958152
Start Date
August 1 2009
End Date
January 1 2010
Last Update
January 7 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Christchurch, New Zealand